Bloomberg reports, citing sources, that Shenzhen Edge Medical Co., Ltd. ("Edge Medical"), a surgical robotics company that previously submitted two IPO applications in Hong Kong, has reportedly secretly applied for a Hong Kong listing, hoping to go public as early as this year with plans to raise approximately $150-200 million. According to sources, Edge Medical has appointed GF Securities and Morgan Stanley to handle the IPO proceedings, with details such as IPO size and timing still to be determined.

Edge Medical, based in Shenzhen and founded in 2017, is a Chinese independently developed surgical robotics company committed to designing, developing, manufacturing, and commercializing surgical robots. It is the first company in China and the second globally to have multi-port, single-port, and bronchoscopy surgical robots all approved for market launch. The company has independently mastered all core technologies involved in surgical robotics, established six major platform technology systems for surgical robots, and built a comprehensive product portfolio including multi-port laparoscopic surgical robots, single-port laparoscopic surgical robots, bronchoscopic surgical robots, and traditional minimally invasive surgical instruments.

Edge Medical previously submitted IPO applications to the Hong Kong Stock Exchange twice, on April 19, 2022, and January 11, 2023, with Morgan Stanley, CICC, and Citigroup serving as IPO underwriters at that time.

The surgical robotics company 'Edge Medical' has once again submitted a prospectus, planning a Hong Kong IPO listing.